Since PSCA-derived peptides were reported to be a target of T-cell-based immunotherapy for advanced prostate cancer [23], the shorter PSCA protein would cause the activation of CD4-positive and/or CD8-positive T cells and subsequently promote epithelial mucosal injury [24]. Here, CD8A is linked to prostate cancer.